Homoharringtonine (Omacetaxine Mepesuccinate) in Patients With Chronic Myeloid Leukemia
- Study Title
- Homoharringtonine (Omacetaxine Mepesuccinate) in Treating Patients With Chronic Myeloid Leukemia (CML) With the T315I BCR-ABL Gene Mutation
- Teva Identifier
- CGX-635-CML-202 | 2006-000176-32
- ClinicalTrials.gov Identifier
- NCT00375219
- Study Status
- Completed
- Trial Condition(s)
- Chronic Myeloid Leukemia
- Interventions
- Drug: Omacetaxine mepesuccinate
- Study Description
- Please refer to ClinicalTrials.gov for a description of the trial
Key Participation Requirements
- Gender
- Female, Male
- Age group
- Adult, Older Adult
- Age Range
- 18 Years and older
- Trial Duration
- 09/01/2006 - 09/01/2013
- Phase
- Phase 2
